BBIO · BridgeBio Pharma, Inc.
$84.12
+1.70% last session
End-of-day data · updated 2026-07-29
Market cap
$17B
Enterprise value
$18B
Trailing P/E
—
Forward P/E
150.4
Dividend yield
—
Beta
0.95
Avg volume
3M
Employees
1K
2D change
1.70%
5D change
—
10D change
5.12%
30D change
18.80%
60D change
29.11%
MTD change
14.80%
YTD change
11.84%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BBIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-16
Latest call per bank · past 12 months
Citigroup
Neutral$93.00
+10.6% vs priceMorgan Stanley
Overweight$98.00
+16.5% vs priceRBC Capital
Outperform$100
+18.9% vs priceJP Morgan
Overweight$94.00
+11.7% vs priceWells Fargo
Overweight$98.00
+16.5% vs priceBarclays
Overweight$80.00
-4.9% vs priceGoldman Sachs
Buy$100
+18.9% vs priceUBS
Buy$82.00
-2.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-16 | Citigroup | Maintains | Neutral | $82.00 → $93.00 |
| 2026-07-13 | HC Wainwright & Co. | Maintains | Buy | $110 → $120 |
| 2026-06-16 | Mizuho | Maintains | Outperform | $106 → $96.00 |
| 2026-06-03 | Canaccord Genuity | Initiates | Buy | $0.00 → $104 |
| 2026-05-28 | Morgan Stanley | Maintains | Overweight | $94.00 → $98.00 |
| 2026-05-28 | HC Wainwright & Co. | Reiterates | Buy | $110 |
| 2026-05-26 | Raymond James | Downgrade | Outperform → Market Perform | $0.00 |
| 2026-05-19 | Citigroup | Initiates | Neutral | $0.00 → $82.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 67 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 17.4% above the 50-day MA ($72.87).
- Price vs 200-day MA: Trading 20.8% above the 200-day MA ($70.84).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.07) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($44.81) and high ($90.17).
BBIO Price Chart
Loading chart for BBIO…
Fundamentals
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.